4.52
0.22%
-0.01
After Hours:
4.63
0.11
+2.43%
VistaGen Therapeutics Inc stock is currently priced at $4.52, with a 24-hour trading volume of 147.08K.
It has seen a -0.22% decreased in the last 24 hours and a -7.57% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.49 pivot point. If it approaches the $4.61 resistance level, significant changes may occur.
Previous Close:
$4.53
Open:
$4.55
24h Volume:
147.08K
Market Cap:
$124.18M
Revenue:
$1.04M
Net Income/Loss:
$-32.07M
P/E Ratio:
-0.7009
EPS:
-6.4491
Net Cash Flow:
$-26.12M
1W Performance:
-3.00%
1M Performance:
-7.57%
6M Performance:
+42.14%
1Y Performance:
+3,065%
VistaGen Therapeutics Inc Stock (VTGN) Company Profile
Name
VistaGen Therapeutics Inc
Sector
Industry
Phone
650 577 3600
Address
343 Allerton Avenue, South San Francisco
VistaGen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
May-20-21 | Initiated | Robert W. Baird | Outperform |
Feb-18-21 | Initiated | Jefferies | Buy |
Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
Jun-27-18 | Initiated | Maxim Group | Buy |
Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
Mar-28-17 | Initiated | Maxim Group | Buy |
View All
VistaGen Therapeutics Inc Stock (VTGN) Latest News
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
Zacks Investment Research
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
Zacks Investment Research
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
Zacks Investment Research
Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment
Benzinga
Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst
Benzinga
VistaGen Therapeutics Inc Stock (VTGN) Financials Data
VistaGen Therapeutics Inc (VTGN) Revenue 2024
VTGN reported a revenue (TTM) of $1.04 million for the quarter ending December 31, 2023, a +386.42% rise year-over-year.
VistaGen Therapeutics Inc (VTGN) Net Income 2024
VTGN net income (TTM) was -$32.07 million for the quarter ending December 31, 2023, a +49.67% increase year-over-year.
VistaGen Therapeutics Inc (VTGN) Cash Flow 2024
VTGN recorded a free cash flow (TTM) of -$26.12 million for the quarter ending December 31, 2023, a +55.00% increase year-over-year.
VistaGen Therapeutics Inc (VTGN) Earnings per Share 2024
VTGN earnings per share (TTM) was -$3.5091 for the quarter ending December 31, 2023, a +62.71% growth year-over-year.
About VistaGen Therapeutics Inc
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):